Substituted Porphyrins

• US 20110065679A1
• Filed: 09/17/2010
• Published: 03/17/2011
• Est. Priority Date: 01/25/1999
• Status: Active Grant

• Current Assignee: Duke University, National Jewish Health
• Original Assignee: Aeolus Pharmaceuticals, Inc.
• Inventors: Gauuan, Polvina Jolicia F., Kitchen, Douglas B., Day, Brian J., Fridovich, Irwin, Trova, Michael P., Batinic-Haberle, Ines, Crapo, James D.
• Granted Patent: US 8,217,026 B2
• Time in Patent Office: Days
• US Class Current: 514/185
• CPC Class Codes: A61K 31/409 having four such rings, e.g. porphine derivatives, bilirubin, biliverdine hemin, hematin A61K31/555
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 39/00 General protective or antinoxious agents
• CPC Class Codes: A61P 39/06 Free radical scavengers or antioxidants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07D 487/22 in which the condensed system contains four or more hetero rings
• CPC Class Codes: C09B 47/00 Porphines; Azaporphines non-dyeing compounds C07D487/22

Abstract

The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.

Claims

1. A method for treating a patient for inflammation of the lung, said method comprising administering to a patient in need an effective amount of a compound of formula

2. The method according to claim 1, wherein said inflammation of the lung is an inflammatory lung disease.

3. The method according to claim 1, wherein said inflammation of the lung is an inflammatory based disorder of asthma, emphysema, acute respiratory distress syndrome (ARDS), pneumonia, cystic fibrosis, or bronchopulmonary dysplasia.

4. The method according to claim 1, wherein said inflammation of the lung comprises respiratory fatigue.

5. The method according to claim 4, wherein said inflammation of the lung is chronic obstructive pulmonary disease.

6. The method according to claim 1, wherein said inflammation of the lung comprises the pulmonary system.

7. The method according to claim 6, wherein said inflammation of the lung is pulmonary fibrosis or pulmonary hypertension.

8. The method according to claim 3, wherein said inflammation of the lung is asthma, emphysema, ARDS or pneumonia.

9. The method according to claim 3, wherein said inflammation of the lung is bronchopulmonary dysplasia.

10. The method according to claim 1, wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.

11. The method according to claim 10, wherein said compound is complexed with manganese.

12. The method according to claim 1, wherein

R₁ and R₃ are —

H, —

CF₃, —

CO₂X,

13. The method according to claim 12, wherein X is methyl or ethyl.

14. The method according to claim 12, wherein R₁, R₂, R₃ and R₄ are the same.

15. The method according to claim 14, wherein

R₁, R₂, R₃ and R₄ are

16. The method according to claim 15, wherein X is methyl or ethyl.

17. The method according to claim 16, wherein said compound is

18. The method according to claim 12, wherein said compound is complexed with a metal selected from the group consisting of manganese, iron, copper, cobalt, nickel or zinc.

19. The method according to claim 18, wherein said compound is complexed with manganese.

20. The method according to claim 19, wherein said compound is